Recent Posts
Nexviazyme Meets All Endpoints in Phase 3 Study for Infantile-Onset Pompe Disease
Sanofi has announced positive results from the Baby-COMET phase 3 study, which evaluated Nexviazyme (avalglucosidase alfa) in infants with infantile-onset Pompe disease (IOPD). The study met its primary endpoint and all secondary endpoints, and Sanofi intends to use...
First Participant Dosed in Phase 1/2 Gene Therapy Trial for Late-Onset Pompe Disease
AskBio has announced that the first participant has been dosed in a phase 1/2 clinical trial evaluating AB-1009, an investigational gene therapy for adults with late-onset Pompe disease (LOPD). AB-1009 is designed to address the underlying cause of Pompe disease by...
First Patients Enrolled in Phase 2 Trial of SRT for Late-Onset Pompe Disease
Shionogi has announced the enrollment of the first patients in a global phase 2 clinical trial evaluating S-606001, an investigational oral therapy for adults with late-onset Pompe disease (LOPD). S-606001 is a substrate reduction therapy (SRT) designed to reduce...
Aro Biotherapeutics reports positive phase 1b results for ABX1100
Aro Biotherapeutics has reported positive topline results from its phase 1b clinical trial of ABX1100, an investigational therapy for adults with late-onset Pompe disease (LOPD). ABX1100 is a substrate reduction therapy (SRT) designed to reduce glycogen production in...
2025 Pompe Empowerment Workshop : Vancouver
This Pompe Empowerment Workshop welcomes patients and their family from BC to MB, for networking, learning and sharing.
What is Pompe disease?
Pompe disease is one of about 50 Lysosomal Storage Disorders. Pompe patients are deficient in the critical enzyme acid alpha-glucosidase.
Connections
Ways to connect with other patients & families and social media opportunities to stay informed.
New Patients and Families
Welcome to the wonderful world of rare disease. It’s a much different world than it was a few years ago. There’s so much information out there, and there are places to turn for support and friendship. With social media, especially Facebook and Twitter, there are answers.
There are patient advocacy groups all over the world, of which CAP is one of them.
Contact Us
Connect with us
Mailing Address
112-3201 Wilson St
Penticton, BC,
Canada
V2A 8J3
Phone: (778) 326-0777, ext 800